Saliva-based Screening Market: By Product Type (Rapid Test Kits, and PCR Based Kits), Technology (Direct Sample to PCR, RT-qPCR, and Lateral Flow Assays), Application (COVID-19 Diagnostics, Infectious Disease Testing, Chronic Disease Screening, and Genetic Testing), End User (Diagnostic Laboratories, Hospitals & Clinics, Academic and Research Institutes, Biopharma Companies, Long Term Care Facilities, and Home Care Settings), and Geography

Saliva-Based Screening Market size was valued at USD 432.1 million in 2023 and poised to grow at a CAGR of 8.1% from 2024-2030.  This growth is driven by a number of factors, including the increasing demand for non-invasive and painless screening methods, the growing awareness of oral health, and the rising prevalence of chronic diseases. Saliva-based screening tests are a type of diagnostic test that uses saliva to detect the presence of disease or other health conditions. Saliva is a readily available and non-invasive biofluid that contains a wealth of information about a person's health. Saliva-based screening tests can be used to detect a variety of diseases, including infectious diseases, such as HIV, hepatitis C, and HPV, chronic diseases, such as diabetes, cancer, and autoimmune diseases, and genetic disorders.

Saliva-based screening tests are becoming increasingly popular due to a number of advantages over traditional screening methods. These advantages include non-invasive and painless collection, easy to perform at home, relatively low cost and high accuracy. In addition, the saliva-based screening market is still in its early stages of development, but it is expected to grow rapidly in the coming years. This growth is driven by the increasing demand for convenient and accurate screening methods, as well as the growing body of research that supports the use of saliva for diagnostics. However, the regulatory landscape for saliva-based screening tests can be complex and vary across different regions. This can create hurdles for manufacturers seeking to bring new tests to market. Key challenges include stringent approval processes, data requirements, and lack of standardized guidelines.

Saliva-Based Screening Market Key Developments:

• In December 2023, Molbio diagnostics, a Goa based company amalgamated with Finland’s testing technologies to commercialize PROMILLESS, a saliva based test kit for measuring body alcohol content. This partnership intended to augment accessibility and advance diagnostics.
• In June 2023, The launch of world’s first saliva based pregnancy test, Salilistic, revolutionized pregnancy detection in United Kingdom. It has eliminated the need for urine and marked a momentous advancement in home pregnancy testing.